Thu, May 13, 2010
Wed, May 12, 2010
[ Wed, May 12th 2010 ] - Market Wire
ENVIROTEK Becomes "SUFFER"
Tue, May 11, 2010
Mon, May 10, 2010
Sun, May 9, 2010
Sat, May 8, 2010
Fri, May 7, 2010
Thu, May 6, 2010
Mon, January 11, 2010
Sat, January 9, 2010
Fri, January 8, 2010
Thu, January 7, 2010
Wed, January 6, 2010
Tue, January 5, 2010
Mon, January 4, 2010
[ Mon, Jan 04th 2010 ] - Market Wire
Cordani Becomes CIGNA CEO
Thu, December 31, 2009
[ Thu, Dec 31st 2009 ] - Market Wire
Quit the Board
Wed, December 30, 2009
[ Wed, Dec 30th 2009 ] - Market Wire
Centric Grants Stock Options
Tue, December 29, 2009

Ligand to Present at the MDB Capital Group Bright Lights Conference on May 11


//health-fitness.news-articles.net/content/2010/ .. al-group-bright-lights-conference-on-may-11.html
Published in Health and Fitness on Thursday, May 6th 2010 at 20:40 GMT by Market Wire   Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that President and Chief Executive Officer John L. Higgins will present at the MDB Capital Group Bright Lights Conference on Tuesday, May 11, 2010, at 1:30 p.m. Eastern time (10:30 a.m. Pacific). The conference takes place at the Palace Hotel in San Francisco.

A live webcast of the presentation will be available on the Companya™s website [ www.ligand.com ]. A replay of the presentation will be archived on the site for 30 days.

About Ligand Pharmaceuticals

Ligand discovers and develops new drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's, inflammatory diseases, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Bristol-Myers Squibb, and Cephalon and more than 30 programs are in various stages of development by its partners.


Publication Contributing Sources